Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?

Eli Lilly is reportedly close to acquiring gene editing partner Verve Therapeutics for up to $1. 3 billion. source: https://tokenist.com/why-are-verve-therapeutics-shares-skyrocketing-in-premarket-trading-today/?utm_source=rss&utm_medium=rss&utm_campaign=why-are-verve-therapeutics-shares-skyrocketing-in-premarket-trading-today